SN Smith & Nephew plc

14.95USD1135.00 GBp · LSE-1.09%Mkt Cap: 12.50B USDP/E: 20.64

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three seg…

Institutional holders11 on file

Key Statistics

Company
Market Cap12.50B USD
Enterprise Value16.71B USD
Revenue (TTM)6.30B USD
Gross Profit4.19B USD
Net Income (TTM)625.00M USD
Revenue/Share7.37 USD
Last Price14.95 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees17.0K
CountryGB
SectorHealthcare
IndustryMedical Devices
ISINGB0009223206
Valuation
P/E (Trailing)20.64
P/E (Forward)13.06
PEG1.10
EV/EBITDA9.18
EV/Revenue2.65
P/S1.51
P/B2.50
EPS (TTM)0.55 USD
EPS (Forward)0.87 USD
52W Range
12.9137% of range18.39
52W High18.39 USD
52W Low12.91 USD
Profitability
Gross Margin68.01%
Oper. Margin14.22%
EBITDA Margin21.94%
Profit Margin10.14%
ROE11.82%
ROA5.98%
ROIC8.53%
ROCE9.67%
Growth
Revenue Growth4.60%
Earnings Growth5.70%
Cash Flow & Leverage
Operating CF1.28B USD
CapEx (TTM)433.00M USD
FCF Margin16.81%
FCF Yield8.47%
Net Debt3.03B USD
Net Debt/EBITDA2.19
Net Debt/FCF2.86
Balance Sheet
Debt/Equity0.63
Current Ratio2.14
Quick Ratio1.11
Book Value/Sh4.54 USD
Cash/Share0.89 USD
Dividends
Fwd Div Rate0.0038 USD
Trail. Div Rate0.0052 USD
Div. Yield2.56%
5Y Avg Yield2.60%
Payout Ratio53.16%
Ex-Div DateOct 1, 2026
Pay Date—
Splits
Last Split9:11
Split DateAug 7, 2000
Analyst Consensus
Rating2.7 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)16.54 USD
Upside (mean)+10.7%
Target Range13.83 USD – 19.38 USD
13.83+10.7% to mean19.38
# Analysts17
Ownership
Shares Out.836.22M
Float842.65M
Insiders0.24%
Institutions75.14%
Technical
SMA 5014.18 (+5.4%)
SMA 20015.07 (-0.8%)
Beta0.67
S&P 52W Chg12.00%
Avg Vol (30d)3.19M
Avg Vol (10d)4.19M
Technical Indicators
RSI (14)52.0
MACD19.9455
MACD Signal24.2661
MACD Hist.-4.3206
BB Upper15.75 USD
BB Middle15.08 USD
BB Lower14.41 USD
BB Width8.86%
ATR (14)0.3533 USD
Vol Ratio (20d)0.87x

About Smith & Nephew (LON: SN)

›

Smith & Nephew (LON: SN) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 17,000 employees.

The shares were at 1135.00 GBp on 19 November 2026, down 11.4% over 52 weeks. Its 52-week range is 980.40 GBp to 1396.50 GBp: the price is 18.7% below the high and 15.8% above the low.

At a market capitalisation of 9.49B GBP, it trades at 20.6 times trailing earnings and 13.1 times forward earnings. The median trailing P/E of its 18 largest Medical Devices peers is 26.3, a discount of 22% for SN. It pays a dividend yielding 2.56% (it pays out 53% of its earnings), against a median of 1.97% among the dividend payers in that peer group.

Smith & Nephew reports return on equity of 11.8%, an operating margin of 14.2% and revenue up 4.6% year over year.

Its debt exceeds its cash by 3.03B USD, a debt-to-equity ratio of 0.63. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 17 analysts cover the stock, with an average rating of Hold; their mean price target of 1256.00 GBp is 10.7% above the current price. The next earnings report is expected on 1 March 2027.